CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
BIA 9-1067drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02092168
NCT02092168Phase 1Completed
CompareCT.gov

Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects

Bial - Portela C S.A.·interventional·Posted Mar 20, 2014·Updated Jan 14, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 for Parkinson Disease. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of age on the pharmacokinetic (PK) profile of BIA 9-1067 and its metabolites.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesFrance
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 20, 2014
Enrollment StartOct 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.3 years ago

Interventions

BIA 9-1067drug